Specialty pharmaceutical company KemPharm, Inc. amended its collaboration and licensing agreement with an affiliate of Gurnet Point Capital (GPC).
Shares of KemPharm Inc. exploded 93% in Wednesday’s pre-market trading session after the US Food and Drug Administration (FDA) approved its treatment for …
Dewey Steadman of research firm Canaccord is chiming in today on shares of KemPharm Inc (NASDAQ:KMPH) from a confident perspective. The analyst assumed …
KemPharm Inc (NASDAQ:KMPH) investors should be smiling from ear to ear today following the news that the company’s Investigational New Drug (IND) application for …
KemPharm Inc KemPharm Inc (NASDAQ:KMPH) shares are falling over 25% after the FDA issued a complete response letter (CRL) to the company for Apadaz, an …